Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson’s disease. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical tri... Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson’s disease. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0.002 | 0.002 | 0.002 | 250000 | 0.002 | DE |
| 12 | 0 | 0 | 0.002 | 0.003 | 0.001 | 284484 | 0.00225906 | DE |
| 26 | -0.001 | -33.3333333333 | 0.003 | 0.004 | 0.001 | 912953 | 0.00248171 | DE |
| 52 | -0.003 | -60 | 0.005 | 0.01 | 0.001 | 1286851 | 0.00548206 | DE |
| 156 | 0.001 | 100 | 0.001 | 0.012 | 0.001 | 3501977 | 0.00526576 | DE |
| 260 | 0.001 | 100 | 0.001 | 0.012 | 0.001 | 3501977 | 0.00526576 | DE |
Flip it
8分前
Flip it
10分前
DrSleep
11分前
Truthfan
14分前
xoom
23分前
peafunke
24分前
Investor082
27分前
gedi8
31分前
brazen22
31分前
jog49
32分前
Flip it
37分前
EOT
37分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。